The total return over the past 12 months is -31.58% vs. +16.94% for the S&P 500. So far it's up -21.13% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (31.58%) | (31.40%) | (41.38%) | (26.92%) | N/A | N/A |
| Total Return CAGR | (31.58%) | (31.40%) | (41.38%) | (26.92%) | N/A | N/A |
| Revenue CAGR | (64.32%) | (34.57%) | (33.60%) | +1.52% | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Coherus Oncology, Inc. (CHRS)
| Year | Start price | End price | CHRS Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $1.42 | $1.12 | (21.13%) | +14.51% | (35.64%) |
| 2025 | $1.38 | $1.42 | +2.90% | +17.72% | (14.82%) |
| 2024 | $3.33 | $1.38 | (58.56%) | +24.89% | (83.45%) |
| 2023 | $7.92 | $3.33 | (57.95%) | +26.19% | (84.14%) |
| 2022 | $15.96 | $7.92 | (50.38%) | (18.17%) | (32.21%) |
| 2021 | $17.38 | $15.96 | (8.17%) | +28.74% | (36.91%) |
| 2020 | $18.01 | $17.38 | (3.47%) | +18.37% | (21.84%) |
| 2019 | $9.05 | $18.01 | +98.95% | +31.22% | +67.73% |
| 2018 | $8.80 | $9.05 | +2.84% | (4.56%) | +7.40% |
| 2017 | $28.15 | $8.80 | (68.74%) | +21.70% | (90.44%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
